Blade Air Mobility, INC

Strata Critical Medical announced a 60.7% year-over-year revenue increase to $72.5 million in Q2 2026, driven by acquisitions and organic growth, alongside improved Adjusted EBITDA and positive operating cash flow.

Strata Critical Medical, Inc. announced the results of its annual meeting of stockholders, including the election of directors and ratification of its independent auditor.

Strata Critical Medical announced first quarter 2026 financial results, showcasing significant year-over-year revenue growth and improved profitability, alongside strategic acquisitions and reiterated full-year guidance.

Strata Critical Medical announced strong fourth quarter 2025 results with an 83.5% year-over-year revenue increase and raised its full year 2026 financial guidance.

Strata Critical Medical, Inc. has closed a $30 million asset-based revolving credit facility, expandable to $50 million, to fund its acquisition strategy while keeping its aircraft fleet unencumbered.

Strata Critical Medical, a leader in organ transplant logistics, expanded its board and appointed healthcare veteran Will Cook as an independent director.

Strata Critical Medical, Inc. announced its second quarter 2026 financial results, showcasing a substantial 60.7% increase in revenue to $72.5 million, primarily driven by strategic acquisitions in its Clinical segment.

Strata Critical Medical, Inc. announced a significant increase in revenue and a return to profitability in its first quarter of 2026, driven by strong performance in both its Logistics and Clinical segments.

Strata Critical Medical reported a significant net income increase in Q3 2025, driven by the divestiture of its Passenger business and strong growth in its core Medical segment, bolstered by the Keystone acquisition.

Blade Air Mobility reported a significant reduction in net loss and a swing to positive Adjusted EBITDA in Q2 2025, alongside the strategic sale of its Passenger business to Joby Aviation for up to $125 million.

Blade Air Mobility saw a revenue increase and a reduction in net losses for the first quarter of 2025, according to its latest 10-Q filing.

Blade Air Mobility's Q3 2024 results show a 5% increase in revenue compared to the same period last year, driven by growth in both passenger and medical transport segments.

Strata Critical Medical, Inc. reported a significant increase in revenue and gross profit for 2025, driven by its focused medical logistics and clinical services strategy following the divestiture of its Passenger business.

Blade Air Mobility's 2024 annual report reveals a 10.4% increase in revenue, driven primarily by growth in its MediMobility Organ Transport segment, while highlighting the company's strategic focus on transitioning to Electric Vertical Aircraft (EVA) technology.

Blade Air Mobility, Inc. reports a 54% increase in revenue for 2023, driven by growth in both its Medical and Passenger segments, while also highlighting ongoing challenges in achieving profitability.

Reginald Love, a Director of Blade Air Mobility, Inc., sold 5,091 shares of common stock on August 10, 2026 for $5.75 per share.

William L. Cook Iii, a Director of Blade Air Mobility, Inc., received 44,438 shares of common stock on July 30, 2026.

Reginald Love, a Director of Blade Air Mobility, Inc., received 37,675 shares of common stock on July 30, 2026.

Edward M Philip, a Director of Blade Air Mobility, Inc., received 30,913 shares of common stock on July 30, 2026.

Robert S Wiesenthal, a Director of Blade Air Mobility, Inc., received 50,234 shares of common stock on July 30, 2026.

Andrew Lauck, a Director of Blade Air Mobility, Inc., received 35,260 shares of common stock on July 30, 2026.

Strata Critical Medical, Inc. (formerly Blade Air Mobility, Inc.) has announced its 2026 Annual Meeting of Stockholders, scheduled for May 28, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Blade Air Mobility, Inc. announces its 2025 Annual Meeting of Shareholders to be held virtually on May 6, 2025, with key voting items including the election of directors and ratification of the accounting firm.

Blade Air Mobility will hold its annual stockholder meeting virtually on May 6, 2025, to vote on director elections, auditor ratification, and executive compensation.

Blade Air Mobility, Inc. files a definitive proxy statement with the SEC.

Blade Air Mobility, Inc. will hold its annual stockholder meeting virtually on May 2, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Velibor Krstic's 1.58 million Strata Critical Medical warrants expired worthless, reducing beneficial ownership to zero.

Investor Velibor Krstic has increased his stake in Strata Critical Medical warrants to 16.21% and is calling for a mandatory exchange to prevent expiration.

Velibor Krstic has increased his beneficial ownership of Strata Critical Medical warrants to 12.4%, citing undervaluation and strategic investment goals.

Velibor Krstic has acquired 764,435 warrants in Strata Critical Medical, Inc., representing 8.3% of the outstanding public warrants, citing undervaluation and potential strategic discussions.

ARK Investment Management LLC and Catherine D. Wood have filed an amendment to their Schedule 13G, reporting beneficial ownership of 3.16% of Strata Critical Medical, Inc. common stock as of June 30, 2026.

Northern Right Capital Management, L.P. and affiliated entities have reported beneficial ownership of approximately 5.1% of Strata Critical Medical, Inc.'s common stock as of June 17, 2026.

ARK Investment Management LLC and Catherine D. Wood have jointly filed a Schedule 13G, reporting beneficial ownership of 8.57% of Strata Critical Medical, Inc. common stock as of March 31, 2026.

BlackRock, Inc. has reported a 5.1% passive ownership stake in Strata Critical Medical Inc.'s Class A Stock as of December 31, 2025.

Third Point LLC and Daniel S. Loeb have disclosed a 5.8% beneficial ownership stake in Strata Critical Medical, Inc. through a Schedule 13G filing.

ARK Investment Management LLC and Catherine D. Wood have reported a 7.52% beneficial ownership stake in Strata Critical Medical, Inc. common stock.